In respiratory, our mission is to work together with healthcare professionals to reduce the individual and societal burden of asthma – a chronic and debilitating condition affecting 30 million people in Europe.1 A better understanding of patient needs, combined with sophisticated science and technology, enables us to develop new and innovative approaches to help those affected by respiratory conditions.
Mundipharma brings more to asthma
In our quest to find better solutions in asthma, we continue to invest in research to identify and shape new ways of helping people with asthma recognise, understand and better manage their condition to lead fuller lives.
Working together with leading respiratory experts, we initiated the REALISE™ (REcognise Asthma and LInk to Symptoms and Experience) survey to uncover some of the underlying reasons for sub-optimal asthma control in Europe. The survey is the largest and most recent survey of its kind and was conducted across 11 European countries in 8,000 people with asthma aged 18-50 who use social media.2-8 REALISE™ revealed a number of psychological factors that may affect a patient’s experience of asthma, such as identity, recognition of symptoms, confidence in disease management and perceptions towards inhaler use. These insights highlight the significant yet underestimated role patient attitudes and behaviours play in asthma management.8
Finding better solutions in asthma management
The continued success and future of Mundipharma respiratory will be driven by a heightened focus on understanding and recognising differences in attitudes and behaviours, including the important role the choice of device can make to patient acceptance and adherence, and collaboration with the medical community and patient groups. Together, we can enable significant advances towards improving disease management and facilitate the development of tailored asthma management strategies, with patients being kept at the forefront. The product range includes:
flutiform® (fluticasone propionate/ formoterol) is a combination of fluticasone propionate, an inhaled corticosteroid, and formoterol fumarate, a long-acting β2-agonist (LABA) therapy, delivered by a pressurised metered-dose inhaler (pMDI).